FDA’s first-cycle review of Dysport® to be completed by year-end: US launch of Dysport® on track

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021